Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by Heinz59on Dec 10, 2018 12:40am
92 Views
Post# 29090186

RE:Looks like it is on the up and up to me

RE:Looks like it is on the up and up to me
quietobserver wrote: Later that month, Vic Neufeld and Cole Cacciavillani of Aphria, George Scorsis and Gabriel Meneses of Scythian and Alejandro Urdaneta, local partner / shareholder of Colcanna, travelled to Colombia to meet with the Colcanna management team and engage in a site visit. During the course of the trip, the parties visited Colcanna’s field operations. The team inspected the farm and participated in a strategy meeting led by Scythian and Colcanna’s management team. As the acquisitions of Colcanna and ABP were being discussed, Scythian put forward the idea of Aphria also acquiring Marigold as part of a proposed Transaction. Scythian believed it could be strategic from both Aphria’s and Scythian’s perspectives to include it as part of a proposed Transaction. On July 10, 2018, Mr. Merton and Mr. Jakob Ripshtein from Aphria travelled to Jamaica to further review the current operations of Marigold. On July 7, 2018, Scythian contacted Clarus to advise the Board on the proposed Transaction. On July 10, 2018, Scythian formally engaged Clarus to assist the Board with its evaluation of the proposed Transaction and to deliver a fairness opinion. On or about July 10, 2018, Scythian and its legal counsel, Gowling WLG (Canada) LLP (“Gowling WLG”), concluded that, given Aphria’s ownership of Shares and warrants of Scythian, the proposed Transaction would constitute a “related party transaction” under MI 61-101 and require, among other things, an independent formal valuation. Given that Clarus was not considered independent to Scythian under MI 61-101, Scythian contacted Haywood. After considering its independence and qualifications, the Board formally engaged Haywood on July 11, 2018 to prepare a formal valuation as required under MI 61-101, as well as to deliver a fairness opinion.



Wow!   That’s Huge!!
Bullboard Posts